Adresse GENETHON - 1 BIS RUE DE L'INTERNATIONALE
91002 EVRY
|
Contact
courriel : galy@genethon.fr
|
Site web :
www.genethon.fr
|
Taille en ETP (sans compter les stagiaires):
supérieure à 50.
|
Descriptif :
INTEGRARE (Integrated genetic approaches in therapeutic discovery for rare diseases, UMR_S951) is a mixed research unit specialized in translational research for the gene therapy of rare genetic disorders. This UMR is located at Généthon, a laboratory of AFM/Téléthon, in partnership with Inserm, the University of Evry - Université Paris Saclay. This partnership offers unique possibilities to translate research discoveries into treatments with possible support in process development, pharmaceutical competencies and a preclinical environment to transform research projects into clinical candidates and innovations. Each of the research laboratories of the UMR is recognized as functional unit directed by group leaders who manage the activity of scientists, technicians, fellows and students on one or more therapeutic or research projects.
|
Année de création :
2010
|
Mission de la structure :
Recherche
|
Mode de gestion de la structure :
Non renseigné.
|
SIRET de la structure :
Non renseigné.
|
Classement scientifique ERC
- LS7 : Prevention, Diagnosis and Treatment of Human Diseases : Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
|
Domaine scientifique
- 5 : Biologie, médecine et santé 2010 0
|
Ecole(s) doctorale(s) de rattachement
-
ED 569 - INNOVATION THÉRAPEUTIQUE: DU FONDAMENTAL À L'APPLIQUÉ, depuis le 01/01/2015, fin d'accréditation le 31/12/2024
-
ED 577 - STRUCTURE ET DYNAMIQUE DES SYSTÈMES VIVANTS, depuis le 01/01/2015, fin d'accréditation le 31/12/2024
|
Rattachée au(x) programme(s) LOLF suivant(s):
Non renseigné
|
Rattachée au(x) thème(s) de recherche suivant(s):
Understanding the physiopathology of diseases of interest with animal or cellular models integrating genetics and vectorology aspects to help design and probe various gene therapies and predict thei;
Technological expertise including conception of new gene delivery tools and omics analyses,;
Understanding the physiopathology of diseases of interest with animal or cellular models integrating genetics and vectorology aspects to help design and probe various gene therapies and predict thei;
Obtaining new proof of concepts for candidate gene therapies and combined approaches with thorough preclinical evaluations including new functional tests, to treat monogenic diseases such as congeni;
|
Liens avec d'autres structures :
Aucun.
|
Site ESR :
Aucun.
|